SKYE Skye Bioscience Company Cash Funds

Corporate company logo of Skye Bioscience, Inc. (SKYE)

Skye Bioscience, Inc. (SKYE) is protected by patents for glaucoma treatment under strict FDA oversight, supported by a team of top-tier biologists. The change in cash balances on the GURU.Markets analytical chart contains up-to-date data, where the value of 0.01 corresponds to the current metric. The implementation of robotics in laboratories is currently accelerating the primary screening of new molecules for future drugs.

Company Liquid Assets: skyebioscience.com (SKYE) for 04/12/2024 - 11/21/2026

Analytical breakdowns and data insights for company Skye Bioscience (SKYE)

Analysis of all company metrics:SKYE Skye Bioscience, Inc.
Brand item of skyebioscience.com

This metric measures the current balance of liquid assets, determining the equilibrium between financial security and capital management efficiency. For Skye Bioscience, Inc. (SKYE), this reserve is critical when conducting costly trials for glaucoma and obesity drugs. By analyzing the company's cash position, an investor assesses the business's ability to withstand biopharmaceutical regulatory risks. The trend of this indicator objectively reflects the issuer's viability in the absence of stable profits.